Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates

admin August 7, 2023

This article was originally published on Nasdaq

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring

Categories: Nasdaq Stocks

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to nests
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .